National Cancer Plan

Baroness Walmsley Excerpts

Monday 9th February 2026 Lords Chamber

[Earl Howe (Con)]

My Lords, I begin by welcoming the publication of the national cancer plan and make it clear we fully share the Government’s desire to tackle cancer and to succeed in the fight against a condition that has affected almost every family in the country in one way or another. The Government have set out a clear ambition in this area, and we support them in that endeavour. It is appropriate for me also to pay tribute to all those who have contributed to the development of the plan, particularly those with lived experience with cancer and those close to them. Their willingness to share their experiences with such openness—and in many cases, courage—has, I am sure, been invaluable in shaping the finished result, and they deserve our thanks and recognition.

The national cancer plan sets out a number of significant commitments, including improving early diagnosis, restoring performance against cancer waiting time standards, accelerating the set-up of clinical trials and rolling out targeted lung screening nationally. It also places a strong emphasis on modernising services through technology and innovation.

These are all laudable aims and, indeed, Cancer Research UK has said that there is “much to welcome” in the plan. However, it has also rightly noted that delivery, funding and accountability will ultimately determine whether patients see real change. It is easy to put ambitious plans down on paper, but what matter in the end are clear delivery milestones and accountability. In that respect, this plan echoes many of the ambitions of the 10-year NHS plan, which was strong on aspiration but lighter on detail about how improvements would be delivered on the ground. My first question is, therefore, straightforward. When will the Government publish clear, fully funded milestones setting out how and when patients can expect to see tangible improvements over the next year or two?

It is also clear that the success of the plan will depend on having a sufficient workforce of cancer nurses, radiographers, pathologists and oncologists to deliver its aims. Can the Minister say whether we will shortly see a fully funded long-term workforce plan to support the staffing required to expand diagnostic and treatment capacity, not just in NHS trust settings but within neighbourhood health centres? In particular, can the Government explain clearly who will staff these services and how they will be funded? Blood Cancer UK has highlighted the importance of ensuring that blood cancers are properly recognised in workforce and service planning, and that patients receive consistent support from the point of diagnosis, including access to a named healthcare professional. Staff also need to know that they will be supported in delivering this plan, given current strains on capacity. In that context, we hear anecdotally of the difficulties involved in ensuring that staffing by doctors is adequate in all parts of the country. Some doctors, especially doctors in training, make up their minds that they will not be sent to work in an area that is not to their liking, perhaps because it would locate them far from friends and family. Will the welcome announcement of more training places in rural areas be enough to get sufficient doctors working in those areas?

Alongside the important question of staffing levels sits the Government’s ambition to invest in up-to-date capital equipment and cutting-edge technology. Investment in this often expensive technology is best and most efficiently met through capital budgets managed centrally. That leads me to a question about accountability for delivery, and where such accountability will lie. With the planned absorption of NHS England into the department, can the Minister give a sense of how the national cancer plan as a whole will be steered and monitored, not only centrally but regionally?

One specific aspect of the plan that I would like to welcome is the dedicated chapter for children, teenagers and young adults. This has been described by the Teenage Cancer Trust as a crucial step and an important acknowledgement that teenagers and young people deserve care designed around them and not as an afterthought. The work that the Government have done in recognising this is welcome. One point that the Teenage Cancer Trust has made particularly clearly is the importance of involving young people at the policy development stage. Can the Minister set out how young people with cancer were engaged in the development of this plan and how their voices were reflected in its content? Looking ahead, what steps will the Government take to ensure this becomes an ongoing process: listening to young people with cancer and systematically taking their feedback into account as the plan is implemented and reviewed?

Another point that charities and campaigners have consistently emphasised is the importance of clearly distinguishing between children and young people. The needs and challenges facing a three year-old child are self-evidently different from those of a 17 year-old young person, and it is important that this distinction is properly recognised in both policy and practice. I would therefore be grateful if the Minister could set out for the House how these different groups within the broader category of children and young people are engaged with. In particular, it would be helpful to understand how mental health support is tailored to different age groups and how the impact of a cancer diagnosis at different stages of a young person’s educational journey is reflected in their treatment and support pathways. If the noble Baroness could confirm that this distinction is one which the Government actively make and which will be taken into account in future policy development, I should be most grateful.

Let me conclude by reiterating my support for this plan and for the ambitions it sets out. In particular, there are some welcome and promising commitments around improving access to clinical trials and speeding up diagnosis. As the Minister knows, we need to do better in both those areas, and we share the Government’s ambitions to do so. For our part, we will continue to play our role in opposition by scrutinising delivery closely to ensure that ambition is matched by action and that the Government’s very laudable commitments translate into tangible improvement on the ground for patients.

[Baroness Walmsley (LD)]

My Lords, from these Benches, we very much welcome the national cancer plan and support its ambitions—and it is very ambitious. Many organisations and committees have called for an integrated, long-term plan, so it is very good that the Government have listened and, in particular, have taken note of the views of patients and their families—the people with lived experience of all these problems. However, may I reiterate Cancer Research UK’s response to the plan? It said:

“The key question that patients and their loved ones will ask, however, is how quickly will they see progress in cancer survival and outcomes? The improvements they are waiting for will depend on how this plan translates into delivery. Funding must match the ambition of what has been promised, or the NHS will struggle to expand its diagnostic capacity or introduce innovation at scale. And clear leadership and accountability are also crucial”.


Many of those points have also been mentioned by the noble Earl, Lord Howe, just now.

We know that outcomes in England have lagged behind comparable countries for decades, so it is positive to see improving cancer survival at the centre of the plan. However, it is going to be tough to achieve and will require much faster progress than what we have heard so far indicates. The key, of course, is improved diagnosis at an early stage, so I welcome the renewed commitment to earlier diagnosis and to meeting all cancer waiting time targets by 2029. It is outrageous that 92% of trusts do not reach the target for starting treatment. I welcome the full rollout of lung screening by 2030 and increasing the sensitivity of the tests used in bowel screening by 2028. However, what about breast screening? There have been problems in some parts of the country in getting that done. Can the Minister say whether these plans will be fully resourced? There is no point in doing the screening and tests unless an expert is there to interpret them. There are bold promises, but will they be matched with the resources and training required?

The plan talks about AI tools and liquid biopsy tests, which could certainly hold real potential for increasing productivity. However, before they are introduced, they must be robustly tested so that only safe and effective innovations reach patients and those that do not work can be dropped.

While there is a focus on diagnosis and treatment, I was pleased to see that the plan includes a commitment to increase action on lifestyle factors which we know cause cancer. Smoking tobacco, being overweight or obese, alcohol and UV exposure still cause many cancers that could be prevented. Fortunately, the Tobacco and Vapes Bill should certainly have a positive effect over the coming years in stopping people smoking in the first place. It is also positive to see action to strengthen protections on sunbed use and measures to drive HPV vaccination uptake, particularly in underserved groups. The new ad hoc committee on childhood vaccine rates is, I hope, going to contribute to that.

More action is needed to drive the shift from sickness to prevention, which is one of the Government’s core objectives in their 10-year health plan. There is still more to do to help millions of existing smokers quit smoking and to prevent someone becoming overweight or obese in the first place. Tightening regulation on alcohol through introducing minimum unit pricing, as implemented in Scotland and Wales, was a missed opportunity. Will the Government reconsider?

Rare cancers make up about 24% of cancers diagnosed in the UK and the EU every year. This includes cancers of children and young people, because they are less likely to suffer from the cancers caused by the lifestyle issues I have just mentioned. This is where research comes in, and the ability to implement research findings into the NHS. It is a sad fact that the NHS has been slow in the past to implement new cutting-edge treatments, so it is welcome that the plan has some important commitments in that respect. However, as with other aspects of the plan, the devil is in the detail.

The focus on ending delays in cancer treatment is a step forward, but funding 28 new radiotherapy machines is not enough when the treatment is so cost-effective and successful. We need to end the radiotherapy deserts. Will the Minister extend her ambition to the 200 extra radiotherapy machines that the Liberal Democrats have proposed? Another 28 will probably only replace the old machines that need to be replaced anyway—it will not take us forward. Can the Minister tell us about the plan to train the operatives for these new machines? Resources, training and accountability are at the heart of this. We have not had a lot of detail yet, so I look forward to getting more.

[The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)]

My Lords, I am grateful for the warm welcome from both Front Benches for the national cancer plan. This is a moment when we transform our cancer care and we make it personalised—we wrap it around the person instead of expecting it to be the other way around. The 62-day treatment standard has not been met since 2015, and outcomes, as we have talked about a lot in this Chamber, continue to lag behind those of comparable countries. That is what has driven us to this point to ensure that, by 2035, three in four people diagnosed with cancer will be alive five years later, whereas at present, the figure is three in five. That represents 320,000 more lives saved, with all the effects on their friends, families and communities, as well as themselves. That will be the fastest improvement in cancer survival this country has ever seen.

I will try to deal with some of the Front-Bench questions. I agree with much of what has been raised, including the recognition of all those, including those with lived experience, who contributed to what is, in my view and experience, a very bold 10-year strategy that actually sets out how we will do this. Both the noble Earl, Lord Howe, and the noble Baroness, Lady Walmsley, asked about clear milestones. I am glad to say that those are set out at the end of each chapter, with dates and the responsible organisations for all key actions and commitments.

The noble Earl raised the workforce plan. It will be published in the spring and will set out guidance—this goes to the point raised by the noble Baroness—not just on expanding numbers but on ensuring that staff are properly trained and supported. This will require a multidisciplinary team approach. We will use training directly as a lever to prioritise training places in trusts, often in the rural and coastal areas that the noble Earl asked about, as it is indeed the case that vacancy rates are higher and performance is lower. Training doctors of course takes time, but this is about long-term sustainable change and about turning around the whole of the cancer pathway. It is the exact opposite of us tinkering here and there. We are working with the royal colleges to boost the numbers of doctors specialising in clinical and medical oncology.

The noble Earl asked about bringing NHS England into the department. I see that as a great opportunity. Within the plan, we have set out a reformed national cancer board. It will be comprised of cancer experts, and it will be accountable—this is so important, as the noble Baroness said—for the overall delivery of the plan. Regionally, we will keep and strengthen the role of cancer alliances, which will work hand in glove with NHS regions to deliver cancer improvements.

The noble Earl asked how young people are being engaged. We worked with the Children and Young People Cancer Taskforce to ensure their voices were heard through its patient experience panel. Importantly, we will appoint a lead for children and young people with cancer to be part of the revamped national cancer board. We want their voices to continue to be heard. We definitely recognise the distinction between children and young people; they have different needs. For example, the plan highlights the importance of play for children, as well as the role of youth support co-ordinators in providing educational, emotional and fertility support for teenagers and young people. I agree with the noble Earl that cancer has a profound psychological impact on all patients and those supporting them. The plan sets out how that support must be standardised for children and young people, including the provision of longer-term support.

The noble Baroness asked about improving early diagnosis. We are providing £2.3 billion of investment in diagnostics to deliver 9.5 million additional tests by 2029 across screening and symptomatic diagnosis. The noble Baroness asked about seeing change; I say go to a community diagnostic centre. That epitomises where we are going with our National Health Service. We will also spend more than £650 million to complete the rollout of lung cancer screening by 2030, which is one of the things that can make the biggest difference in more disadvantaged areas, as well in prevention.

On radiotherapy machines, the responsibility lies at a local level. We expect local systems to continue to invest in new machines to meet the ambitious targets. Through the spending review, providers have been allocated with £15 billion in operational capital for local priorities and £5 billion to support a return to constitutional standards, including for radiotherapy machines.